Ligand/Lundbeck file Carbella at FDA for Epilepsy

Ligand Pharmaceuticals Incorporated Captisol licensee Lundbeck LLC announced that the FDA has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014.

Carbella (carbamazepine) Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.